216 related articles for article (PubMed ID: 11366017)
1. Maintaining a low viral load with Nevirapine?
TreatmentUpdate; 1998 Dec; 10(10):3-4. PubMed ID: 11366017
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
[TBL] [Abstract][Full Text] [Related]
4. Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
Yamamoto Y; Yasuoka A; Yasuoka C; Genka I; Teruya K; Kikuchi Y; Tachikawa N; Oka S
Jpn J Infect Dis; 2000 Dec; 53(6):244-5. PubMed ID: 11227023
[No Abstract] [Full Text] [Related]
5. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Haubrich R; Richman D
JAMA; 1999 Jan; 281(2):130-1. PubMed ID: 9917108
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Lallemant M; Ngo-Giang-Huong N; Jourdain G; Traisaithit P; Cressey TR; Collins IJ; Jarupanich T; Sukhumanant T; Achalapong J; Sabsanong P; Chotivanich N; Winiyakul N; Ariyadej S; Kanjanasing A; Ratanakosol J; Hemvuttiphan J; Kengsakul K; Wannapira W; Sittipiyasakul V; Pornkitprasarn W; Liampongsabuddhi P; McIntosh K; Van Dyke RB; Frenkel LM; Koetsawang S; Le Coeur S; Kanchana S;
Clin Infect Dis; 2010 Mar; 50(6):898-908. PubMed ID: 20158398
[TBL] [Abstract][Full Text] [Related]
7. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
[TBL] [Abstract][Full Text] [Related]
8. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
9. Viral load--how low is best?
TreatmentUpdate; 1998 Dec; 10(10):2-3. PubMed ID: 11366016
[TBL] [Abstract][Full Text] [Related]
10. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
11. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
12. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
Conway B; Wainberg MA; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange JM; Montaner JS
AIDS; 2001 Jul; 15(10):1269-74. PubMed ID: 11426071
[TBL] [Abstract][Full Text] [Related]
13. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM;
AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059
[TBL] [Abstract][Full Text] [Related]
14. Nevirapine approved by FDA. Food and Drug Administration.
Bowersox J
NIAID AIDS Agenda; 1996 Sep; ():10. PubMed ID: 11363918
[TBL] [Abstract][Full Text] [Related]
15. Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
Am J Health Syst Pharm; 1998 Jun; 55(11):1106, 1108. PubMed ID: 9626369
[No Abstract] [Full Text] [Related]
16. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine triple combo results released.
Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362346
[TBL] [Abstract][Full Text] [Related]
18. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Clay PG; Rathbun RC; Slater LN
JAMA; 1999 Jan; 281(2):130; author reply 131. PubMed ID: 9917107
[No Abstract] [Full Text] [Related]
19. Viramune triple combo reduces viral load below limit of detection.
AIDS Patient Care STDS; 1997 Dec; 11(6):456. PubMed ID: 11361870
[No Abstract] [Full Text] [Related]
20. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Raboud JM; Rae S; Vella S; Harrigan PR; Bucciardini R; Fragola V; Ricciardulli D; Montaner JS
J Acquir Immune Defic Syndr; 1999 Nov; 22(3):260-6. PubMed ID: 10770346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
